Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle.

ABSTRACT:

SUBMITTER: Taylor RS 

PROVIDER: S-EPMC524116 | biostudies-literature | 2004 Oct

REPOSITORIES: biostudies-literature